Page 317 - fbkCardioDiabetes_2017

Hypertension in Elderly Population 293

6. Mohan JC. Prevalence, awareness, treatment and control and risk factors 24. SRS Statistical Report 2011: SRS Statistical Report Tables. Available at:
of hypertension in India and its neighborhood: Newer data and older per- http://www.censusindia.gov.in/vital_statistics/SRS_Report/12S RS%20Sta-
spective. Indian Heart J 2006;58:7-9. tistical%20Report%20Table%20-%2020111.pdf [Accessed on Septem-
ber 15, 2013].
7. Anderson GH, Blackman N, Streeten DH. The effect of age on prevalence
of secondary forms of hypertension in 4429 consecutively referred patients.
J Hyperns 1994;12:609-15.
8. Chobanian AV, Bakris GL, Black HL. Seventh report of the Joint National
Committee on Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure. Hypertension 2003;42:1206-52.
9. National High Blood Pressure Education Program Working Group. Report
on Hypertension in the elderly.Hypertension 1994;23:275-85.
10. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with
various anti-hypertensive therapies used as first line agents: a network
meta-analysis. JAMA 2003;289:2534-44.
11. Major outcomes in high risk hypertensive patients randomized to angioten-
sin converting enzyme inhibitor or calcium channel blocker vs diuretic. The
Antihypertensive and Lipid-Lowering Treatment to prevent Heart Attack
Trial (ALLHAT). JAMA 2002; 288:2981-97.
12. Staessen JA, Fagard R. Thijs L, et al. Randomised double blind comparison
of placebo and active treatment for older patients with isolated systolic
hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Inves-
tigators. Lancet 1997; 350:757-64.
13. SHEP Cooperative Research Group. Prevention of stroke by antihyperten-
sive drug treatment in older persons with isolated systolic hypertension.
JAMA 1996;265:3255-64.
14. Schiffrin EL. Effects of antihypertensive drugs on vascular remodeling: do
they predict outcome in response to antihypertensive therapy? Curr Opin
Nephrol Hypertens 2001;10:617-24.
15. Yusuf S, Sleight P, Progue J. Effects of angiotensin converter inhibitor ,
ramipril, on cardiovascular events in high risk patients. The out comes Pre-
vention Evaluation Study Investigators. N Engl J Med 2000; 342:145-53.
16. Linholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mor-
tality in patients with diabetes in the losartan intervention for End point
reduction in hypertension study (LIFE): a randomized trial against atenolol.
Lancet 2002;359:1004-10.
17. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO.
Morbidity and mortality in the Swedish Trail in Old patients with hyper-
tension. Lancet 1991;338:315-9.
18. Frishman WH, Landau A, Cretkovic A. Combination drug therapy with
calcium-channel blockers in the treatment of systemic hypertension. J
Clin Pharmacol 1993;33:752-5
19. Madhukumar S, Gaikwad V, Sudeepa D. An Epidemiological study of Hy-
pertension and its risk factors in Rural Population of Bangalore Rural
District. Al Ameen J Med Sci. 2012; 5(3):264-70.
20. Pradeepa R, Mohan V. Hypertension and pre hypertension in developing
countries. Indian J Med Res 2008; 128:688-90.
21. Hafez G, Bagchi K, Mahaini R. Caring for the elderly: A report on the
status of care for the elderly in the Eastern Mediterranean Region. East
Mediterr Health J. 2000; 6(4):636-43.
22. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, et al.
ACCF/AHA 2011 Expert Consensus Document on Hypertension in the
Elderly. A Report of the American College of Cardiology Foundation Task
Force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2011;
57(20):2037-114.
23. World health organization: World Health Day. Available at: http://www.
who.int/world-healthday/previous/en/index.html [Accessed on September
15, 2013].

Cardio Diabetes Medicine